Yiquan Wu Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 5A24
- BETHESDA, MD, 20892
- 240-858-3266
- yi-quan.wu@nih.gov
RESEARCH SUMMARY
Dr. Wu is a Research Fellow at the National Cancer Institute (NCI/NIH), actively involved in collaborative research with clinicians and lab researchers. The focus of his work is to discover novel approaches for treating diseases caused by Kaposi's sarcoma-associated herpesvirus and other oncogenic viruses. Through pre-clinical research focused on cancer cell viability, immune surface marker expression, signaling pathways, and cell cycle checkpoints, Dr. Wu's studies have contributed to the development of two clinical trials—one for Kaposi sarcoma and one planned for KSHV-multicentric Castleman disease.
Areas of Expertise
Yiquan Wu Ph.D.
Biography
Yiquan Wu Ph.D.
After completing his undergraduate and master work at Huazhong Agricultural University in 2012, Dr. Wu received his doctoral degree from Ludwig Maximilian University of Munich in 2017. In his graduate work, he found PDGFR-α as an entry receptor for human cytomegalovirus by binding to the virus’s gH/gL/gO complex. In 2017, he started his postdoctoral research in the laboratory of Dr. Robert Yarchoan in the HIV and AIDS Malignancy Branch of the CCR. In 2022, he became a Research Fellow in the team. During the time in NCI, his research has been focused on developing new therapeutical agents to treat caused by Kaposi's sarcoma-associated herpesvirus and other oncogenic viruses. His studies have led to the development of two clinical trials of these agents, one for Kaposi sarcoma and one for KSHV-multicentric Castleman disease.